Treehill was engaged by a European private biotech.
The company was developing an oncology asset in phase 2 studies. Initially, it had access to $60 million in finance.
Orchestrated a data-led pivot away from orphan oncology.
Selected autoimmunity as the more appropriate target therapeutic area for future development.
Prepared the business case for the development strategies that corresponded with each of the commercial opportunities.
Evaluated the potential commercial opportunities throughout the field.
Treehill redirected the clinical development program accordingly. This gave confidence to existing investors as well as attracted new investors to enable the next financing round.
Orchestrated a data-led pivot away from orphan oncology.
Selected autoimmunity as the more appropriate target therapeutic area for future development.
Selected autoimmunity as the more appropriate target therapeutic area for future development.
Selected autoimmunity as the more appropriate target therapeutic area for future development.
Orchestrated a data-led pivot away from orphan oncology.
Selected autoimmunity as the more appropriate target therapeutic area for future development.
Prepared the business case for the development strategies that corresponded with each of the commercial opportunities.
Evaluated the potential commercial opportunities throughout the field.
